Detect Clinician Activity Shifts Earlier to Improve Market Readiness
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Life sciences organizations have more data than ever, yet many sources used to guide commercial strategy reveal market change weeks or months after it begins. This webinar explores how teams can now detect shifts in clinical activity faster and use that intelligence to understand market response and emerging opportunities.
A new source of intelligence derived directly from clinical language and activity within the EHR can reveal changes in the diseases, treatments, brands, clinical concepts, and terminology clinicians are documenting. These EHR-derived signals provide an earlier view into emerging market and geographic trends before they become apparent in traditional downstream data.
Featured speakers will examine how commercial teams can use this intelligence to identify where market opportunities and changes may be emerging. Attendees will also learn how comparing clinical activity before, during, and after brand campaigns and field initiatives can add a new dimension to impact measurement.
Rather than replacing claims, Rx, or other established data sources, this approach provides a different signal from the earliest point in the clinical journey.
Register to learn how EHR-derived clinical intelligence can reveal market shifts and help commercial teams make more informed decisions earlier.
Who should attend
- Commercial and Brand leaders
- Commercial Analytics and Insights professionals
- Sales and Field Force Effectiveness teams
- Medical Affairs and Medical Strategy leaders
- Field Medical/MSL leaders
- Medical Insights and Medical Excellence professionals
- Launch Excellence professionals
- Competitive Intelligence professionals
- Omnichannel/Customer Engagement teams
What you will learn
- How clinician activity signals drawn from documentation behavior can reveal emerging disease, treatment, brand, competitive and geographic trends earlier than traditional downstream real-world data
- How Commercial and Medical Affairs teams can use these signals to identify where opportunities are emerging and prioritize field, brand and medical initiatives
- How pre-, during- and post-initiative clinician activity measurements can help teams assess response to brand campaigns, field activity, medical education, congresses, publications and other interventions
Featured Speakers
Joseph Zabinski, PhD, MEM
Joseph Zabinski, PhD, MEM, joined IMO Health in 2025 as Senior Vice President of Product Management. He leads the Life Sciences product portfolio and go-to-market strategy. Dr. Zabinski is a published authority and thought leader in AI-driven personalization and outcome prediction using healthcare data. Previously, he oversaw the AI & Personalized Medicine business unit at OM1, a real-world evidence and technology provider.
Dr. Zabinski began his career as a Consultant at McKinsey, advising pharmaceutical clients on AI strategy and implementation. He holds a PhD from UNC Chapel Hill’s Gillings School of Global Public Health, where his research focused on Bayesian graphical modeling applied to large healthcare datasets. He also earned an MEM in Engineering Management from Dartmouth, a BS in Physics and German Studies from Boston College and a Fulbright Fellowship to Austria.
Ediz Calay, PhD
Dr. Ediz Calay is Vice President of Product Management at IMO Health, where he leads the strategy and development of solutions that help healthcare and life sciences organizations derive greater value from clinical data. He is responsible for driving innovation across data intelligence, interoperability and advanced analytics initiatives that support healthcare decision-making, clinical research and real-world evidence generation.
Prior to joining IMO Health, Dr. Calay led real-world evidence and analytics initiatives for pharmaceutical organizations, leveraging machine learning and advanced data science methodologies to generate insights from real-world healthcare data. Dr. Calay holds a PhD in Biological Sciences in Public Health from Harvard University, with a concentration in Biochemistry and completed a fellowship in Biophysics at the Harvard T.H. Chan School of Public Health.
Partner for this event
IMO Health
IMO Health is an AI-native clinical data intelligence company helping provider, health tech, and life sciences organizations transform complex healthcare data into accurate, reliable insights. Built on decades of expert-curated clinical terminology and accountable AI, we deliver trusted clinical context that advances research, accelerates innovation, and enhances patient care.